VXRT Vaxart

Vaxart Announces Positive Hamster Challenge Study Data for its Oral COVID-19 Vaccine

Vaxart Announces Positive Hamster Challenge Study Data for its Oral COVID-19 Vaccine
EN
14/10/2020

Underlying

VXRTVaxart

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Vaxart

 PRESS RELEASE
Free
VXRT VAXART

Vaxart Announces Withdrawal of Reverse Stock Split Proposal

Vaxart Announces Withdrawal of Reverse Stock Split Proposal SOUTH SAN FRANCISCO, Calif., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, announced that it has withdrawn its reverse stock split proposal. “After careful consideration, we have decided to officially withdraw our reverse stock split proposal. Moving forward, we will continue to communicate frequently with our stockholders across multiple channels...

September 19, 2025 1 EN
 PRESS RELEASE
Free
VXRT VAXART

Vaxart Appoints W. Mark Watson as Lead Independent Director

Vaxart Appoints W. Mark Watson as Lead Independent Director In process of adopting a Director stock ownership policy to reinforce commitment of aligning the Board’s interests with stockholders Vaxart encourages all stockholders of record on July 29, 2025, who have not yet voted FOR the reverse stock split, to do so by 11:59 p.m. Eastern Time on September 18, 2025 SOUTH SAN FRANCISCO, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platf...

September 17, 2025 1 EN
 PRESS RELEASE
Free
VXRT VAXART

Vaxart Reports Additional Phase 1 Data Supporting the Potential Effica...

Vaxart Reports Additional Phase 1 Data Supporting the Potential Efficacy of its Second-Generation Norovirus Oral Pill Vaccine Candidate - Second-generation constructs induce robust increases in fecal IgA, which was shown to be correlated with protection against infection in the company’s previous Phase 2b challenge study - SOUTH SAN FRANCISCO, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today reported additional positive data f...

September 10, 2025 1 EN
 PRESS RELEASE
Free
VXRT VAXART

Vaxart Announces Adjournment of Special Meeting of Stockholders

Vaxart Announces Adjournment of Special Meeting of Stockholders Meeting adjourned to September 19, 2025 at 8:30 a.m. Pacific Time Adjournment provides stockholders with more time given changes in Board composition, additional governance change considerations and future potential disclosures Vaxart encourages all stockholders of record on July 29, 2025 who have not yet voted to do so by 11:59 p.m. Eastern Time on September 18, 2025 SOUTH SAN FRANCISCO, Calif., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (“Vaxart” or the “Company”) announced today that its 2025 s...

September 8, 2025 1 EN
 PRESS RELEASE
Free
VXRT VAXART

Vaxart to Present at the H.C. Wainwright Global Investment Conference ...

Vaxart to Present at the H.C. Wainwright Global Investment Conference on September 8, 2025 SOUTH SAN FRANCISCO, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- SOUTH SAN FRANCISCO, Calif., September 2, 2025 — Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced that management will present at the H.C. Wainwright Global Investment Conference taking place September 8-10, 2025. Presentation Details:Date and Time: Monday, September 8 at 12:00 PM ETWebcast:  A...

September 3, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch